These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 22934253)
21. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis. Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136 [TBL] [Abstract][Full Text] [Related]
22. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873 [TBL] [Abstract][Full Text] [Related]
23. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Deuker MM; Marsh Durban V; Phillips WA; McMahon M Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943 [TBL] [Abstract][Full Text] [Related]
24. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
25. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. Carroll MJ; Parent CR; Page D; Kreeger PK BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130 [TBL] [Abstract][Full Text] [Related]
26. Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. Al Hashmi M; Sastry KS; Silcock L; Chouchane L; Mattei V; James N; Mathew R; Bedognetti D; De Giorgi V; Murtas D; Liu W; Chouchane A; Temanni R; Seliger B; Wang E; Marincola FM; Tomei S J Transl Med; 2020 May; 18(1):192. PubMed ID: 32393282 [TBL] [Abstract][Full Text] [Related]
27. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Boni A; Cogdill AP; Dang P; Udayakumar D; Njauw CN; Sloss CM; Ferrone CR; Flaherty KT; Lawrence DP; Fisher DE; Tsao H; Wargo JA Cancer Res; 2010 Jul; 70(13):5213-9. PubMed ID: 20551059 [TBL] [Abstract][Full Text] [Related]
28. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF Ngiow SF; Meeth KM; Stannard K; Barkauskas DS; Bollag G; Bosenberg M; Smyth MJ Oncoimmunology; 2016 Mar; 5(3):e1089381. PubMed ID: 27141346 [TBL] [Abstract][Full Text] [Related]
29. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863 [TBL] [Abstract][Full Text] [Related]
31. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Deken MA; Gadiot J; Jordanova ES; Lacroix R; van Gool M; Kroon P; Pineda C; Geukes Foppen MH; Scolyer R; Song JY; Verbrugge I; Hoeller C; Dummer R; Haanen JB; Long GV; Blank CU Oncoimmunology; 2016; 5(12):e1238557. PubMed ID: 28123875 [TBL] [Abstract][Full Text] [Related]
32. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235 [TBL] [Abstract][Full Text] [Related]
33. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Shahabi V; Whitney G; Hamid O; Schmidt H; Chasalow SD; Alaparthy S; Jackson JR Cancer Immunol Immunother; 2012 May; 61(5):733-7. PubMed ID: 22382362 [TBL] [Abstract][Full Text] [Related]
34. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946 [TBL] [Abstract][Full Text] [Related]